Latest News

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

The FDA granted approval daratumumab and hyaluronidase combined with bortezomib, lenalidomide, and dexamethasone for induction and consolidation for patients with newly diagnosed multiple myeloma eligible for ASCT.